{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:13:47Z","timestamp":1782260027318,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jjcc.2016.06.007","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T20:09:23Z","timestamp":1468958963000},"page":"648-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention"],"prefix":"10.1016","volume":"69","author":[{"given":"Tomoya","family":"Hoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Gosho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Aonuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2016.06.007_bib0100","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.amjcard.2008.08.021","article-title":"Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy","volume":"102","author":"Rossini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1540-8183.2009.00468.x","article-title":"Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting","volume":"22","author":"Rubboli","year":"2009","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0110","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/CIRCINTERVENTIONS.113.000179","article-title":"Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range","volume":"6","author":"Naruse","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/eurheartj\/eht461","article-title":"Triple antithrombotic therapy in cardiac patients: more questions than answers","volume":"35","author":"Moser","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jjcc.2015.10.019","article-title":"Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation","author":"Konishi","year":"2016","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0125","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archinte.165.7.784","article-title":"Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction","volume":"165","author":"Buresly","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0130","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"Sorensen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0135","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0140","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jjcc.2014.08.013","article-title":"Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting","volume":"65","author":"Kawai","year":"2015","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0155","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu283","volume":"35","author":"Authors\/Task Force Members","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0160","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0165","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0180","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","volume":"169","author":"Gibson","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2016.06.007_bib0185","unstructured":"ClinicalTrials.gov. Evaluation of dual therapy with dabigatran vs. triple therapy with warfarin in patients with AF that undergo a PCI with stenting (REDUAL-PCI). Last updated May 12, 2016; Accessed May 29, 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02164864."},{"key":"10.1016\/j.jjcc.2016.06.007_bib0190","unstructured":"ClinicalTrials.gov. Study apixaban to vitamin K antagonist for the prevention of stroke or systemic embolism and bleeding in patients with non-valvular atrial fibrillation and acute coronary syndrome\/percutaneous coronary intervention. Last updated May 13, 2016; Accessed May 29, 2016. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02415400."}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508716301344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508716301344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:57:08Z","timestamp":1760273828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508716301344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0914508716301344"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2016.06.007","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2016.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}